TSE:4587Biotechs
Assessing PeptiDream (TSE:4587) Valuation After Weak 2025 Results And New 2026 Profit Outlook
Earnings miss and fresh guidance put PeptiDream (TSE:4587) under the spotlight
PeptiDream (TSE:4587) has drawn investor attention after releasing full year 2025 results showing sharply lower sales and a net loss, alongside new 2026 guidance that outlines management’s expectations for revenue and profit.
See our latest analysis for PeptiDream.
The latest guidance appears to have stabilised sentiment in the very short term, with a 1 day share price return of 0.74% and 7 day share price return...